Interview with the Co-founder and CEO of Abalone Bio, Richard Yu

The Co-Founder & CEO of Abalone Bio, Richard Yu is talking about Abalone Bio’s cutting-edge antibody modulator technologies for challenging specific GCPRs.

These next-generation therapies aim to tackle unmet medical needs at the intersection of inflammation, fibrosis and pain. Their lead programs, including ABt285, are pioneering solutions for conditions like chemotherapy-induced peripheral neuropathy and liver fibrosis with a strong emphasis on precision and safety. ABt285 avoids psychoactive effects, the risk of metabolic side effects, and issues related to chronic use and tolerance, setting new standards in therapeutic innovation for pain and inflammation management.

Read the Bioneex Story with Abalone Bio